BCAX - Company ID 0002023658
Bicara Therapeutics Inc. trades as BCAX and has a market capitalization of $1.95 B, making it the #2159 largest US-listed company by market value. This page tracks Bicara Therapeutics Inc. through 220 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider sale notice | 144 | 2026-05-21 |
| Major company event | 8-K | 2026-05-21 |
| Insider trade | 4 | 2026-05-20 |
| Insider sale notice | 144 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider sale notice | 144 | 2026-05-15 |
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC • Bicara Therapeutics Inc.
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) • Bicara Therapeutics Inc.
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update • Bicara Therapeutics Inc.
Bicara is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara has built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This approach was deployed in the development of Bicara’s lead program ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor (EGFR) directed monoclonal antibody bound to a human transforming growth factor beta (TGF-β) ligand trap. By combining these two clinically validated targets, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment (TME). Ficerafusp alfa directs the TGF-β inhibitor into the immediate TME through the binding of EGFR on tumor cells, whi
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) • Bicara Therapeutics Inc.
The largest companies sharing Bicara Therapeutics Inc.'s SEC industry classification (pharmaceutical preparations).
Bicara Therapeutics Inc. (BCAX) has a market capitalization of $1.95 B as of 2026-07-09, ranking #2159 among US-listed companies.
In its latest fiscal year Bicara Therapeutics Inc. reported a net loss of $137.95M.